7 rezultatet
OBJECTIVE
Stroke is a major cause of disability. Certain experimental studies have suggested that a combination of almitrine + raubasine (Duxil) increases the supply of oxygen to cerebral tissues and may be beneficial in post-stroke rehabilitation. This multicentre clinical study was carried out in
Cerebral hemodynamic and metabolic changes, occurring during delayed hypoperfusion following transient cerebral ischemia, and the influence of treatment with almitrine plus raubasine were studied in mongrel dogs. 10 min of transient cerebral ischemia was induced by bilateral clamping of both carotid
Positron emission tomography and oxygen-15 were used to evaluate the effect of almitrine-raubasine combination on cerebral blood flow and oxidative metabolism in patients with cerebral ischemia. In five patients aged between 58 and 74 years, with a cerebral ischemic accident in the territory of the
Different pharmacological properties of almitrine-raubasine show that this combination may be a good therapy for the treatment of age-related cerebral disorders and functional rehabilitation after stroke. Many clinical studies have been carried out in France and in the rest of Europe, confirming the
BACKGROUND
Almitrine-raubasine combination (brand name Duxil), has been considered as an alternative treatment for dementia.
OBJECTIVE
To determine the clinical efficacy and safety of Duxil in the treatment of patients with dementia.
METHODS
We searched the Cochrane Dementia and Cognitive
According to an epidemiological study of cerebrovascular disease carried out in China in 1986, the prevalence, incidence, and mortality rates were 159.93/100,000, 115.61/100,000, and 31.33/100,000, respectively. These figures were high compared to available epidemiological data for the rest of the
ISKEDYL (PF 50), which is sold as a vasoregulator of cerebral irrigation, consists of a mixture of dihydroergocristine and raubasine. This work aims at determining possible interactions between this product and certain drugs used in anesthesia from the cardiovascular point of view. ISKEDYL does not